RELMADA THERAPEUTICS, INC. Unearned Premiums
RELMADA THERAPEUTICS, INC. (RLMD) had Unearned Premiums of $2.30 thousand as of 2022-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Liabilities
us-gaap:UnearnedPremiums · last filed 2023-05-11
- 2022-03-31: Unearned Premiums $2.30K.
- 2021-12-31: Unearned Premiums $4.00K.
| Period end | Unearned Premiums |
|---|---|
| 2022-03-31 | $2.30K 10-Q · filed 2023-05-11 |
| 2021-12-31 | $4.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |